File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antidepressant use and risk of self-harm among people aged 40 years or older: A population-based cohort and self-controlled case series study

TitleAntidepressant use and risk of self-harm among people aged 40 years or older: A population-based cohort and self-controlled case series study
Authors
KeywordsAntidepressants
CDARS
Depression
Hong Kong
Older adults
Self-harm
Suicide
Issue Date2022
Citation
The Lancet Regional Health - Western Pacific, 2022, v. 27, article no. 100557 How to Cite?
AbstractBackground: Studies on the association between antidepressants and self-harm in adults were mostly conducted over a decade ago and have inconsistent findings. We aimed to compare self-harm risks by antidepressant classes among people aged 40 years or older with depression. Methods: Individuals aged ≥40 years with depression who initiated antidepressant treatment between 2001 and 2015 were retrieved from the Hong Kong Clinical Data Analysis & Reporting system, and were followed up until December 31, 2016. We conducted self-controlled case series (SCCS) analyses to estimate the incidence rate ratio (IRR) of self-harm comparing the pre-exposure (90 days before the first antidepressant use), index exposure (the first antidepressant use), and subsequent exposure (subsequent antidepressant use) periods to nonexposed periods. We applied Cox proportional hazard regressions to estimate the hazard ratio (HR) of self-harm comparing five antidepressant classes (tricyclic and related antidepressant drugs [TCAs], selective serotonin reuptake inhibitors [SSRIs], noradrenergic and specific serotonergic antidepressants [NaSSAs], serotonin–norepinephrine reuptake inhibitors [SNRIs], and others). Findings: A total of 48,724 individuals were identified. SCCS analyses (N = 3,846) found that the increased self-harm risk occurred during the pre-exposure (IRR: 22.24; 95% CI, 20.25-24.42), index exposure (7.03; 6.34-7.80), and subsequent exposure periods (2.47; 2.18-2.79) compared to the unexposed period. Cohort analyses (N = 48,724) found an association of higher self-harm risks in short-term (one year) for NaSSAs vs. TCAs (HR, 2.13; 95% CI, 1.53-2.96), SNRIs vs. TCAs (1.64; 1.01-2.68), and NaSSAs vs. SSRIs (1.75; 1.29-2.36) in the 40-64 years group. The higher risk remained significant in long-term (> one year) for NaSSAs vs. TCAs (1.55; 1.26-1.91) and NaSSAs vs. SSRIs (1.53; 1.26-1.87). In the 65+ group, only short-term differences were observed (SSRIs vs. TCAs [1.31; 1.03-1.66], SNRIs vs. SSRIs [0.44; 0.22-0.87], and SNRIs vs. NaSSAs [0.43; 0.21-0.87]). Interpretation: Within-person comparisons did not suggest that antidepressant exposure is causally associated with an increased risk of self-harm in people with depression. Between-person comparisons revealed differences in self-harm risks between certain pairs of antidepressant classes. These findings may inform clinicians’ benefit-risk assessments when prescribing antidepressants. Funding: Nil.
Persistent Identifierhttp://hdl.handle.net/10722/336869
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChai, Yi-
dc.contributor.authorLuo, Hao-
dc.contributor.authorMan, Kenneth K.C.-
dc.contributor.authorLau, Wallis C.Y.-
dc.contributor.authorChan, Sherry K.W.-
dc.contributor.authorYip, Paul S.F.-
dc.contributor.authorWong, Ian C.K.-
dc.date.accessioned2024-02-29T06:57:05Z-
dc.date.available2024-02-29T06:57:05Z-
dc.date.issued2022-
dc.identifier.citationThe Lancet Regional Health - Western Pacific, 2022, v. 27, article no. 100557-
dc.identifier.urihttp://hdl.handle.net/10722/336869-
dc.description.abstractBackground: Studies on the association between antidepressants and self-harm in adults were mostly conducted over a decade ago and have inconsistent findings. We aimed to compare self-harm risks by antidepressant classes among people aged 40 years or older with depression. Methods: Individuals aged ≥40 years with depression who initiated antidepressant treatment between 2001 and 2015 were retrieved from the Hong Kong Clinical Data Analysis & Reporting system, and were followed up until December 31, 2016. We conducted self-controlled case series (SCCS) analyses to estimate the incidence rate ratio (IRR) of self-harm comparing the pre-exposure (90 days before the first antidepressant use), index exposure (the first antidepressant use), and subsequent exposure (subsequent antidepressant use) periods to nonexposed periods. We applied Cox proportional hazard regressions to estimate the hazard ratio (HR) of self-harm comparing five antidepressant classes (tricyclic and related antidepressant drugs [TCAs], selective serotonin reuptake inhibitors [SSRIs], noradrenergic and specific serotonergic antidepressants [NaSSAs], serotonin–norepinephrine reuptake inhibitors [SNRIs], and others). Findings: A total of 48,724 individuals were identified. SCCS analyses (N = 3,846) found that the increased self-harm risk occurred during the pre-exposure (IRR: 22.24; 95% CI, 20.25-24.42), index exposure (7.03; 6.34-7.80), and subsequent exposure periods (2.47; 2.18-2.79) compared to the unexposed period. Cohort analyses (N = 48,724) found an association of higher self-harm risks in short-term (one year) for NaSSAs vs. TCAs (HR, 2.13; 95% CI, 1.53-2.96), SNRIs vs. TCAs (1.64; 1.01-2.68), and NaSSAs vs. SSRIs (1.75; 1.29-2.36) in the 40-64 years group. The higher risk remained significant in long-term (> one year) for NaSSAs vs. TCAs (1.55; 1.26-1.91) and NaSSAs vs. SSRIs (1.53; 1.26-1.87). In the 65+ group, only short-term differences were observed (SSRIs vs. TCAs [1.31; 1.03-1.66], SNRIs vs. SSRIs [0.44; 0.22-0.87], and SNRIs vs. NaSSAs [0.43; 0.21-0.87]). Interpretation: Within-person comparisons did not suggest that antidepressant exposure is causally associated with an increased risk of self-harm in people with depression. Between-person comparisons revealed differences in self-harm risks between certain pairs of antidepressant classes. These findings may inform clinicians’ benefit-risk assessments when prescribing antidepressants. Funding: Nil.-
dc.languageeng-
dc.relation.ispartofThe Lancet Regional Health - Western Pacific-
dc.subjectAntidepressants-
dc.subjectCDARS-
dc.subjectDepression-
dc.subjectHong Kong-
dc.subjectOlder adults-
dc.subjectSelf-harm-
dc.subjectSuicide-
dc.titleAntidepressant use and risk of self-harm among people aged 40 years or older: A population-based cohort and self-controlled case series study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.lanwpc.2022.100557-
dc.identifier.scopuseid_2-s2.0-85135693444-
dc.identifier.volume27-
dc.identifier.spagearticle no. 100557-
dc.identifier.epagearticle no. 100557-
dc.identifier.eissn2666-6065-
dc.identifier.isiWOS:000844045200001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats